A national, multicenter, prospective, observational study to assess patient characteristics, treatment algorithms and disease management of hyperkalaemia patients with chronic kidney disease or under dialysis or with heart failure, treated with sodium zirconium cyclosilicate in Greece - SHIELD

Study identifier:D9480R00055

ClinicalTrials.gov identifier:NCT06185660

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A national, multicenter, prospective, observational study to assess patient characteristics, treatment algorithms and disease management of hyperkalaemia patients with chronic kidney disease or under dialysis or with heart failure, treated with sodium zirconium cyclosilicate in Greece

Medical condition

Hyperkalaemia

Phase

N/A

Healthy volunteers

No

Study drug

sodium zirconium cyclosilicate (SZC)

Sex

All

Estimated Enrollment

120

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 09 Feb 2024
Estimated Primary Completion Date: 31 Mar 2025
Estimated Study Completion Date: 31 Mar 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria